Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

Biliary tract cancer (BTC) refers to several cancers of the biliary system, and covers a range of invasive adenocarcinomas, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma.

Read full article